[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07639632":3,"trial-entities:NCT07639632":100,"trial-summary:NCT07639632":105},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":19,"study_type":22,"primary_purpose":23,"phases":24,"enrollment_info":26,"interventions":29,"primary_outcomes":38,"secondary_outcomes":42,"sex":48,"minimum_age":49,"maximum_age":50,"healthy_volunteers":14,"eligibility_criteria":51,"std_ages":66,"locations":69,"central_contacts":89,"overall_officials":95,"references":98,"see_also_links":99},"NCT07639632","HSC-MS-26-0099","Reduce Inefficiencies in Management of Spasticity","NOT_YET_RECRUITING","2029-11-30","2026-06","2026-06-12","2026-06-15","The University of Texas Health Science Center, Houston","OTHER",false,"The purpose of this study is to evaluate the effectiveness of a spasticity screener and to determine if the spasticity screener results are useful to healthcare providers and impact clinical decision making",null,[18],"Stroke",[20,21],"acute ischemic stroke","intracerebral hemorrhage","INTERVENTIONAL","DIAGNOSTIC",[25],"NA",{"count":27,"type":28},80,"ESTIMATED",[30,34],{"type":13,"name":31,"description":32,"armGroupLabels":33},"Screener","Participants will be screened for spasticity using the 2 question version of the Post-stroke Spasticity Monitoring Questionnaire (PSMQ) at 2 days after discharge, 2 weeks post stroke, 1 month post stroke, 3 months post stroke and every 3 months after for a total of 12 screenings across 24 months",[31],{"type":13,"name":35,"description":36,"armGroupLabels":37},"Standard of care","Observational data for the standard of care group will be obtained via phone every 3 months post stroke up to 24 months, utilizing the Standard of Care Group Questionnaire.",[35],[39],{"measure":40,"timeFrame":41},"Time to detect spasticity from incidence of stroke","From baseline to 24 months after stroke",[43,46],{"measure":44,"description":45,"timeFrame":41},"Time to referral for spasticity from incidence of stroke","Evaluate average time to referral to neurology or Physical Medicine \\& Rehabilitation (PM\\&R)",{"measure":47,"timeFrame":41},"The time from incidence of stroke to Botulinum neurotoxin (BoNT) administration","ALL","18 Years","80 Years",{"inclusion":52,"exclusion":59,"raw_text":65},[53,54,55,56,57,58],"Currently admitted for an acute hemorrhagic or ischemic stroke; recurrent stroke allowed if no spasticity at baseline","NIHSS score of \\> 0 on items 5 or 6 (required of at least 1 limb)","Willingness to participate in the study for 24 months","Able to sign consent form or availability of a legally authorized representative to sign","Able to read\u002Fwrite in English","Identified MD for follow up post hospitalization",[60,61,62,63,64],"Botulinum toxin use for any indication within the past 12 weeks","Acute life threatening illness","Prior limb injury or neurological diagnosis that limited movement in the now affected limb(s)","Any terminal illness that would limit participation in study follow ups","Known spasticity or other movement disorders that impact tone","Inclusion Criteria:\n\n* Currently admitted for an acute hemorrhagic or ischemic stroke; recurrent stroke allowed if no spasticity at baseline\n* NIHSS score of \\> 0 on items 5 or 6 (required of at least 1 limb)\n* Willingness to participate in the study for 24 months\n* Able to sign consent form or availability of a legally authorized representative to sign\n* Able to read\u002Fwrite in English\n* Identified MD for follow up post hospitalization\n\nExclusion Criteria:\n\n* Botulinum toxin use for any indication within the past 12 weeks\n* Acute life threatening illness\n* Prior limb injury or neurological diagnosis that limited movement in the now affected limb(s)\n* Any terminal illness that would limit participation in study follow ups\n* Known spasticity or other movement disorders that impact tone",[67,68],"ADULT","OLDER_ADULT",[70],{"facility":71,"city":72,"state":73,"zip":74,"country":75,"contacts":76,"geoPoint":86},"The University of Texas Health Science Center at Houston PO Box 20036","Houston","Texas","77030","United States",[77,82],{"name":78,"role":79,"phone":80,"email":81},"Sean I Savitz, MD","CONTACT","713-500-7083","Sean.I.Savitz@uth.tmc.edu",{"name":83,"role":79,"phone":84,"email":85},"Harriet M Sales","(713) 500-7849","harriet.mari.sales@uth.tmc.edu",{"lat":87,"lon":88},29.76328,-95.36327,[90,92],{"name":78,"role":79,"phone":91,"email":81},"(713) 500-7083",{"name":93,"role":79,"phone":94,"email":85},"Harriet Sales","(713) 500-7037",[96],{"name":78,"affiliation":71,"role":97},"PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":101,"biomarkers":104},[102,103,18],"Acute Ischemic Stroke","Cerebral Hemorrhage",[],{"nct_id":4,"found":14,"summary":16,"prompt_version":16}]